Varesi Angelica, Deumer Undine-Sophie, Ananth Sanjana, Ricevuti Giovanni
Department of Biology and Biotechnology, University of Pavia, 27100 Pavia, Italy.
Almo Collegio Borromeo, 27100 Pavia, Italy.
J Clin Med. 2021 Oct 29;10(21):5077. doi: 10.3390/jcm10215077.
The well-known symptoms of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) are chronic pain, cognitive dysfunction, post-exertional malaise and severe fatigue. Another class of symptoms commonly reported in the context of ME/CFS are gastrointestinal (GI) problems. These may occur due to comorbidities such as Crohn's disease or irritable bowel syndrome (IBS), or as a symptom of ME/CFS itself due to an interruption of the complex interplay between the gut microbiota (GM) and the host GI tract. An altered composition and overall decrease in diversity of GM has been observed in ME/CFS cases compared to controls. In this review, we reflect on genetics, infections, and other influences that may factor into the alterations seen in the GM of ME/CFS individuals, we discuss consequences arising from these changes, and we contemplate the therapeutic potential of treating the gut to alleviate ME/CFS symptoms holistically.
肌痛性脑脊髓炎/慢性疲劳综合征(ME/CFS)的著名症状包括慢性疼痛、认知功能障碍、运动后不适和严重疲劳。在ME/CFS背景下通常报告的另一类症状是胃肠道(GI)问题。这些问题可能由于克罗恩病或肠易激综合征(IBS)等合并症而出现,或者作为ME/CFS本身的一种症状,是由于肠道微生物群(GM)与宿主胃肠道之间复杂相互作用的中断所致。与对照组相比,在ME/CFS病例中观察到GM的组成改变和多样性总体下降。在本综述中,我们思考了可能导致ME/CFS个体GM改变的遗传学、感染及其他影响因素,讨论了这些变化产生的后果,并思考了通过治疗肠道来整体缓解ME/CFS症状的治疗潜力。